
MindMed’s (NASDAQ:MNMD) recurring collaborator, Prof. Dr. Matthias Liechti of the University Hospital Basel (UHB), will lead a novel Phase 1 clinical trial aiming to compare acute responses to R-MDMA, S-MDMA and MDMA in healthy subjects, which is set to begin on Tuesday.
The study will compare the acute subjective, physiological and endocrine effects of R-MDMA, S-MDMA and racemic -that is, a mixture with equal amounts of its component S and R enantiomers- MDMA in 24 unimpaired volunteers.